Screenshot 2021-06-24 at 18.22_edited.jpg
APNSCxHKSAN logo square-02.png

Hybrid Exhibition
1 - 3 October 2021

Foyer, William Mong M.W. Building,
LKS Faculty of Medicine,
The University of Hong Kong

Roundtable Session Sponsor

054B4D9E-6EE6-4F48-A4D1-A6292FBDE0DF.png
36946492-ABA0-499B-A371-F1E234631947.jpeg

LIXIANA ® - Superior reduction in major bleeding vs. well-managed warfarin

1

1. Giugliano RP, et al. N Engl Med. 2013; 369 (22): 2093-2104.

LIXIANA ® - The only NOAC with significant reduction in CV and all cause mortality in Asian

2*

2. Chiang CE, et al. J Arrhythm. 2017; 33: 345-367.

NOAC: Novel oral anticoagulants; CV: cardiovascular

* Compare with warfarin

66BFA343-86CA-411C-AAB3-43E5AF22E49D.jpeg
35B296D7-7F03-4BF8-9B88-68921E98EAEE.jpeg

LIXIANA ® - Can be co-administered with other commonly used cardiovascular agents

3,4

3. Steffel J, et al. EP Europace, 2021; euab065, Available at https://doi.org/10.1093/europace/euab065. Last accessed on 16 Aug, 2021

4. Hong Kong Lixiana Package Insert Jul 2019.

Contact us

Shirley Cheung

Email: ZZHK0008@daiichisankyo.com.hk

Company Website: www.daiichisankyo.com.hk